GlaxoSmithKline's chronic cough therapy launched Phase 3 clinical trials in China
I'm PortAI, I can summarize articles.
GlaxoSmithKline's chronic cough therapy has started Phase 3 clinical trials in China. Bellus Health has initiated a study in China to evaluate the efficacy and safety of BLU-5937 in treating refractory chronic cough. The study aims to assess the effectiveness and safety of BLU-5937 in adult patients with refractory chronic cough. This study is led by Academician Zhong Nanshan and Director Lai Kefang of the First Affiliated Hospital of Guangzhou Medical University. The company is also conducting two other clinical trials, with data expected in the second half of 2025. This news constitutes significant corporate event information
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments